Understanding the Role of Lp(a) as a CV Risk Marker to Therapeutic Target in the Prevention of ASCVD
Residual ASCVD risk may be present even after the optimization of LDL-C levels and increasing evidence has suggested that elevated Lp(a) is an emerging CVD risk factor that has been shown to be a causal CVD risk factor in epidemiological and genetic studies, as well as enha
Category
  • CMHC
Format
  • Self-study / Enduring
Credits
  • 1.50 ACPE Pharmacy
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC
  • 1.50 CDE
  • 1.50 Participation
Ace the Case Challenge Series: Exploring Novel Strategies for LDL-C Combination Therapy to Decrease ASCVD Risk
Effectively managing high cholesterol level and safely lowering LDL-C is crucial for preventing and reducing the risk of adverse cardiovascular events. However, achieving LDL-C goals remains suboptimal, particularly in high-risk and very high-risk patients.
Category
  • CMHC
Format
  • Self-study / Enduring
Credits
  • 0.75 ACPE Pharmacy
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC
  • 0.75 Participation
Ace the Case Challenge Series: The Intersection of MASH and Cardiometabolic Risk
This Ace the Case Series is designed to be quick and offer high-level takeaways and pearls.Case #1:  A 37-Year-Old Man with Incidental Hepatic Steatosis on Abdominal Ultrasound
Category
  • CMHC
Format
  • Self-study / Enduring
Credits
  • 0.50 ACPE Pharmacy
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC
  • 0.50 CDE
  • 0.50 Participation
The Burden of Resistant Hypertension in Women: Novel and Emerging Approaches to Improve Outcomes
This activity consists of a recorded presentation at the 2024 Women's Health and Wellness Masterclass, held in April 2024 in Dana Point, CA.  The session, "The Burden of Resistant Hypertension in Women: Novel and Emerging Approaches to Improve Outcomes" was presented by Debbie Cohen, MD
Category
  • CMHC
Format
  • Self-study / Enduring
Credits
  • 0.50 ACPE Pharmacy
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC
  • 0.50 Participation

Pages